Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV
Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment